Viatris Inc. VTRS

Revenue Intelligence Report • 20 quarters of SEC filing data • Updated 2026-03-15

Viatris Inc. has a forecasted full-year revenue of $14B, a -5.6% year-over-year change, based on 20 quarters of SEC filing data. Key revenue drivers include R&D (elasticity 0.71x). The ARDL model achieves strong accuracy at 0.6% MAPE.

Investment Thesis

Our ARDL model tracks Viatris Inc.'s revenue with exceptional precision (0.6% MAPE), indicating highly predictable cash flows. R&D investment shows a 0.71x multiplier — each 1% increase in R&D spend is associated with a 0.71% revenue increase, signaling strong innovation-to-revenue conversion.

Next FY Revenue
$13.6B
-5.6% YoY
R&D Elasticity
0.71x
SG&A Elasticity
-16.20x
Model Accuracy
0.6% MAPE
Holdout validation: The model predicted $3.6B vs the actual $3.8B — an error of 4.7%.
⚠ Model limitation: This company shows negative spending multipliers, meaning increases in spending have not directly translated into revenue growth. This typically occurs with commodity-driven companies or hypergrowth companies.

Revenue Forecast

VTRS Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q3 2025 $3.6B $3.8B $3.5B – $3.6B -5.6% ✗ Outside range
Q4 2025 $3.0B $3.0B – $3.1B -19.1%
Q2 2026 $3.7B $3.6B – $3.8B +13.8%
Q3 2026 $3.9B $3.8B – $4.0B +8.7%
Q4 2026 $2.9B $2.8B – $3.0B -22.4%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Viatris Inc.'s systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 1.0018 +0.2% In line with trend 5
FQ2 (Dec–Feb) 1.0015 +0.2% In line with trend 1
FQ3 (Mar–May) 0.9981 -0.2% In line with trend 5
FQ4 (Jun–Aug) 0.9986 -0.1% In line with trend 5

How Spending Drives Revenue

VTRS Spending Timing
Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. Model: ARDL (log-log) with 20 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

CRL COO RMD ELV WST HOLX ISRG MCK